Family medicine clinicians managing Type 2 diabetes now have comparative head-to-head data positioning a GLP-1 receptor agonist directly against insulin glargine, the longstanding basal insulin standard of care, in a large trial population that mirrors the high-cardiovascular-risk, overweight patients seen daily in primary care. This evidence base is directly actionable for clinicians deciding when to initiate or transition therapy in patients who might otherwise default to insulin intensification. The inclusion of cardiovascular risk as an enrollment criterion reinforces the clinical framework in which GLP-1 class agents are increasingly preferred as first-line injectable therapy over insulin in appropriate patients.
A recent head-to-head trial enrolled more than 2,700 adults with Type 2 diabetes who were overweight or carried high cardiovascular risk, comparing Eli Lilly’s efsitora alfa (Foundayo), a once-weekly basal insulin, against insulin glargine, a once-daily basal insulin standard of care. The trial was designed to evaluate glycemic control and safety across a population highly relevant to everyday clinical practice, where basal insulin remains a cornerstone of management for patients who have not achieved adequate control on oral agents or other injectables.
Foundayo demonstrated non-inferiority to insulin glargine in HbA1c reduction, with comparable rates of hypoglycemia observed between the two arms, supporting the therapeutic equivalence of the once-weekly formulation. For prescribers managing patients who struggle with daily injection adherence, the availability of a once-weekly basal insulin represents a meaningful clinical option, particularly in populations with high cardiovascular risk where consistent glycemic control contributes to long-term outcomes. These findings position efsitora alfa as a practical alternative to daily basal insulin in Type 2 diabetes management, with the potential to improve adherence and reduce treatment burden without sacrificing efficacy or safety.
Foundayo (retatrutide) and Wegovy (semaglutide) represent two distinct approaches to GLP-1 based therapy, with Foundayo acting as a triple agonist targeting GIP, GLP-1, and glucagon receptors, while Wegovy focuses on GLP-1 receptor activation alone. A head-to-head comparison of Foundayo against insulin glargine in over 2,700 adults with Type 2 diabetes who were overweight or carried elevated cardiovascular risk provides meaningful real-world relevant data for clinicians choosing between injectable therapies. These findings reinforce that the GLP-1 therapy landscape is rapidly expanding beyond single-receptor agents, offering patients more options tailored to their metabolic and cardiovascular profiles. When counseling patients already on or considering GLP-1 therapy, family medicine clinicians should proactively address how newer multi-receptor agonists differ from established options in terms of mechanism, expected weight loss magnitude, and tolerability so patients can make informed, expectation-aligned decisions.
“The head-to-head data comparing Foundayo against insulin glargine in over 2,700 adults with Type 2 diabetes is exactly the kind of comparative effectiveness evidence our field has needed. What stands out to me clinically is that we are finally moving beyond placebo-controlled trials and starting to benchmark these newer agents against the standards of care patients are already on. For those of us managing complex metabolic patients, this reshapes the conversation from ‘should we add a GLP-1’ to ‘is there any remaining justification to stay on insulin glargine as a first intensification step.’ In practice, I am now walking into visits armed with this data to help patients who have been on basal insulin for years understand that a meaningful, evidence-backed alternative exists that may serve their cardiovascular and glycemic goals more effectively.”
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is Foundayo and how does it differ from Wegovy?
Foundayo is Eli Lilly’s GLP-1 based therapy for Type 2 diabetes, while Wegovy is Novo Nordisk’s semaglutide product primarily approved for weight management. Both work through the GLP-1 receptor pathway but differ in their active compounds, dosing schedules, and approved indications.
What type of patients were included in the Foundayo clinical trial?
The study enrolled more than 2,700 adults who had Type 2 diabetes and were either overweight or at high cardiovascular risk. This population reflects the real-world patients most likely to benefit from GLP-1 based therapies in clinical practice.
How was Foundayo tested compared to existing diabetes treatments?
Foundayo was compared directly against insulin glargine, which is a long-acting basal insulin that has been a standard treatment option for Type 2 diabetes for many years. Head-to-head comparisons with insulin are considered a rigorous benchmark for evaluating new diabetes therapies.
Is Wegovy only for weight loss or can it help with diabetes too?
Wegovy is FDA-approved for chronic weight management, but semaglutide, its active ingredient, also has strong evidence supporting blood sugar control in Type 2 diabetes under a different brand name, Ozempic. Your physician can help determine which formulation and indication best matches your clinical needs.
Are GLP-1 medications safe for people who already have heart disease?
Several GLP-1 receptor agonists, including semaglutide, have demonstrated cardiovascular benefit in large outcomes trials involving patients with established heart disease. Patients at high cardiovascular risk were specifically included in the Foundayo study, which speaks to the importance of this patient population in GLP-1 research.
Can I take a GLP-1 medication instead of insulin if I have Type 2 diabetes?
For some patients with Type 2 diabetes, GLP-1 receptor agonists can reduce or delay the need for insulin, and the Foundayo trial directly compared this approach against basal insulin therapy. This is a clinical decision that depends on your individual blood sugar levels, kidney function, and other health factors.
What does being overweight have to do with needing a GLP-1 medication?
Excess body weight worsens insulin resistance and accelerates the progression of Type 2 diabetes, so GLP-1 medications address both conditions simultaneously by improving blood sugar control and promoting meaningful weight reduction. This dual benefit is part of why GLP-1 therapies have become central to modern metabolic medicine.
How do I know if Foundayo or Wegovy is the right GLP-1 therapy for me?
The choice between available GLP-1 therapies depends on your specific diagnosis, whether the primary goal is blood sugar control, weight reduction, or cardiovascular risk reduction, and how your body tolerates different dosing regimens. A physician experienced in GLP-1 and metabolic medicine can review your full clinical picture and guide that decision.
Do GLP-1 medications work better in people who are overweight versus those who are not?
Clinical trials generally show meaningful metabolic benefits across a range of body weights, though patients with higher baseline body weight often experience more pronounced weight reduction. The inclusion of overweight participants in the Foundayo trial reflects the reality that most patients with Type 2 diabetes carry excess weight.
What should I ask my doctor before starting a GLP-1 therapy like Foundayo or Wegovy?
You should ask about the approved indications, expected benefits for your specific conditions, potential side effects such as nausea or gastrointestinal symptoms, and how success will be monitored over time. Understanding how a GLP-1 therapy fits into your broader treatment plan, including any existing medications, is essential before starting.
